title: Interstitial granulomatous drug reaction to sorafenib.
authors.forename: Cristina
authors.initials: C
authors.lastname: Martínez-Morán
authors.forename: Laura
authors.initials: L
authors.lastname: Nájera
authors.forename: Ana I
authors.initials: AI
authors.lastname: Ruiz-Casado
authors.forename: Alberto
authors.initials: A
authors.lastname: Romero-Maté
authors.forename: Pablo
authors.initials: P
authors.lastname: Espinosa
authors.forename: Carmen
authors.initials: C
authors.lastname: Meseguer-Yebra
authors.forename: Susana
authors.initials: S
authors.lastname: Córdoba
authors.forename: Jesús M
authors.initials: JM
authors.lastname: Borbujo
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006099:Granuloma / Q000139:chemically induced* / Q000473:pathology; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib